The proteinuria market reached a value of USD 1.5 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 2.9 Billion by 2035, exhibiting a growth rate (CAGR) of 6.28% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year |
2024
|
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 1.5 Billion |
Market Forecast in 2035
|
USD 2.9 Billion |
Market Growth Rate (2025-2035)
|
6.28% |
The proteinuria market has been comprehensively analyzed in IMARC's new report titled "Proteinuria Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Proteinuria refers to a medical condition characterized by the presence of excess protein in the urine. It does not cause noticeable symptoms on its own and is often detected through urine tests during routine check-ups or when investigating other health concerns. However, in some patients, proteinuria may be accompanied by various signs and indications, such as foamy or frothy urine, swelling in the hands, feet, or face (edema), unexplained weight gain, fatigue, frequent urination, etc. Diagnosing the ailment involves a series of steps to determine the presence, severity, and underlying cause of excess protein in the urine. Initially, a healthcare provider may perform a urine dipstick test, which offers a qualitative assessment of protein levels. If proteinuria is detected, further diagnostic tests, such as a urine protein-to-creatinine ratio (PCR) or albumin-to-creatinine ratio (ACR), are conducted to get a more accurate measure of protein excretion. In some cases, a 24-hour urine collection may be performed to quantify the total amount of protein excreted. Additionally, numerous imaging studies, including ultrasound and CT scans, may be conducted to assess kidney structure and function. If necessary, a renal biopsy is also performed to evaluate kidney tissue and identify the underlying cause of proteinuria.
The escalating cases of kidney diseases, such as glomerulonephritis, diabetic nephropathy, nephrotic syndrome, etc., which affect the filtering units of the kidneys, thereby leading to abnormal protein leakage into the urine, are primarily driving the proteinuria market. Furthermore, the rising incidence of several associated risk factors, including urinary tract infections (UTIs), preeclampsia, genetic predisposition, congestive heart failure, hypertension, etc., is also bolstering the market growth. In addition to this, the widespread adoption of renoprotective medications, such as mineralocorticoid receptor antagonists and endothelin receptor antagonists, for slowing the progression of kidney damage in patients is creating a positive outlook for the market. Moreover, several key players are making extensive investments in research activities to develop novel immunomodulatory drugs that target specific inflammatory pathways and aid in reducing protein leakage. This, in turn, is also acting as another significant growth-inducing factor. Additionally, the emerging popularity of the fractional excretion of proteins (FEP) test, since it helps to differentiate between various types of proteinuria and provides insights into the site as well as the mechanism of protein leakage, is expected to drive the proteinuria market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the proteinuria market in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for proteinuria and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the proteinuria market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current proteinuria marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Market Insights
Epidemiology Insights
Proteinuria: Current Treatment Scenario, Marketed Drugs and Emerging Therapies